filmov
tv
Expert Video Report on biomarkers for immune checkpoint blockade in patients with solid tumours
Показать описание
Reporting onsite from AACR 2022 in New Orleans, Benoit Rousseau reviews the results from a study looking at the occurrence of POLE defects to predict the activity of nivolumab in solid tumours, and to specify the range of TMB application as a biomarker for immune checkpoint blockade. He further reviews the CheckMate 848 results comparing nivo+ipi vs nivo alone in metastatic solid tumours with high TMB, supporting the predictive value of TMB rather from tumour rather than from blood samples.
Abstracts:
CT021 - PD-1 blockade in solid tumors with defects in polymerase epsilon - Benoît Rousseau, et al.
CT022 - CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden - Michael Schenker, et al.
Produced by the European Society for Medical Oncology
Abstracts:
CT021 - PD-1 blockade in solid tumors with defects in polymerase epsilon - Benoît Rousseau, et al.
CT022 - CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden - Michael Schenker, et al.
Produced by the European Society for Medical Oncology
0:03:41
0:09:57
0:00:46
0:00:55
0:04:18
0:00:51
0:00:59
0:03:12
0:04:41
0:09:04
0:02:23
0:24:54
0:03:33
0:00:51
1:02:59
0:01:13
0:05:26
0:28:52
0:00:58
0:07:16
0:02:40
1:00:13
0:18:38
0:10:44